Locations:

Research

June 29, 2017/Cancer/Research

Non-Cytotoxic Epigenetic Therapy for p53-Mutant/p16-Deleted Solid and Liquid Cancers

Three clinical trials underway

June 19, 2017/Cancer/Research

Study Warns Against De-Intensifying Treatment for Certain Oropharyngeal Cancer Patients

Not all HPV-positive patients have good prognoses

June 5, 2017/Cancer/Research

Time to Treat is Increasing, Associated with Worsened Survival

Cleveland Clinic study of 3.7 million patients

June 5, 2017/Cancer/Research

Study Suggests Some Small Cell Lung Cancer Patients Benefit from Immune Checkpoint Inhibitor

Pembrolizumab stabilizes cancer in some patients

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

June 5, 2017/Cancer/Research

Trial Finds Maximum Tolerable Dose for Combination Therapy for Metastatic Renal Cell Carcinoma Patients

Axitinib and crizotinib stabilized disease in most

June 4, 2017/Cancer/Research

Maximum Tolerable Doses for Adding Cell Checkpoint Inhibitor to Standard of Care for Glioblastoma Patients

Inhibitor stops DNA repair of cancer cells

June 3, 2017/Cancer/Research

A Novel Approach: Aggressive Chemotherapy Regimen Before Surgery in Resectable Pancreatic Adenocarcinoma

May increase some pancreatic cancer survival rates

May 23, 2017/Cancer/Research

A New Strategy for Cancer Treatments

Moving from whack-a-mole to chess

May 8, 2017/Cancer/Research

Promising New Combination Therapy for Advanced, HER2+ Breast Cancer Shown Safe and Effective

Neratinib and trastuzumab emtansine (T-DM1) combination potent and well tolerated

March 15, 2017/Cancer/Research

Cleveland Clinic Researcher Receives $5.5 Million Outstanding Investigator Award

Maciejewski honored for work in bone marrow failure syndromes

BackPage 28 of 31Next